Risk of Bias Analysis of Systematic Reviews of Probiotics for Treatment of Irritable Bowel Syndrome

Jordan Shapiro; Jessica Bernica; Ruben Hernaez

doi:10.1016/j.cgh.2018.07.010

Risk of Bias Analysis of Systematic Reviews of Probiotics for Treatment of Irritable Bowel Syndrome

Clin Gastroenterol Hepatol. 2019 Mar;17(4):784-785. doi: 10.1016/j.cgh.2018.07.010. Epub 2018 Aug 8.

Authors

Jordan Shapiro¹, Jessica Bernica², Ruben Hernaez³

Affiliations

¹ Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas. Electronic address: jordan.shapiro@bcm.edu.
² Internal Medicine Residency Program, Department of Medicine, Baylor College of Medicine, Houston, Texas.
³ Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas; Section of Gastroenterology, Michael E. DeBakey VA Medical Center, Houston, Texas.

PMID: 30012436
DOI: 10.1016/j.cgh.2018.07.010

Abstract

Global prevalence of irritable bowel syndrome (IBS) is between 7% and 21%.¹ Pathogenesis of IBS symptoms such as pain, altered bowel habits, and bloating is multifactorial, with central and peripheral mechanisms serving as targets for treatments.² Probiotics have been studied for the treatment of IBS and are well tolerated and safe.³.

MeSH terms

Adult
Humans
Irritable Bowel Syndrome / therapy*
Probiotics / administration & dosage*
Publication Bias / statistics & numerical data*
Risk Assessment
Systematic Reviews as Topic*
Treatment Outcome